Kidney transplant immunosuppressants of today. 2. Transplant immunosuppressive agents

Drugs of Today

Volumn 33, Issue 4, 1997, Pages 221-236

  Shoker, Ahmed S ^a  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; 2 (3 DIMETHYLAMINOPROPYL) 8,8 DIPROPYL 2 AZASPIRO[4.5]DECANE; ANTISENSE OLIGONUCLEOTIDE; AZATHIOPRINE; BREQUINAR; CELL ADHESION MOLECULE; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; LEFLUNOMIDE; MIZORIBINE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POLYCLONAL ANTIBODY; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS;

BONE DISEASE; BONE MARROW SUPPRESSION; CADAVER KIDNEY; CATARACT; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; GENE TRANSFER; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERTENSION; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; REVIEW;

EID: 0030972103     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. United States Renal Data System. USRDS 1994 Annual Data Report. National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, Bethesda 1994 and Am J Kidney Dis 1994, 24(Suppl. 2): S1-181.
2. United States Renal Data System. USRDS 1994 Annual Data Report. National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, Bethesda 1994 and Am J Kidney Dis 1994, 24(Suppl. 2): S1-181.
3. Almond, P.A., Mata, A., Gillingham, K.J. et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993, 55: 752.
4. Gjertson, D. Survival trends in long-term first cadaver-donor kidney transplants. In: Clinical Transplants. Terasaki, P.I., Cecka, J.M. (Eds.). UCLA Tissue Typing Laboratory: Los Angeles 1991, 225-35.
5. Rao, K.V., Kasiske, B.L., Bloom, P.M. Acute graft rejection in the late survivors of renal transplantation. Transplantation 1989, 47: 290.
6. Didlake, R.H., Dreyfus, K., Kerman, R.H. et al. Patients noncompliance: A major cause of late graft failure in CsA-treated renal transplants. In: Cyclosporine: Therapeutic Use in Transplantation. Kahan, B.D. (Ed.). Grune and Stratton: Orlando 1988, 63-69.
7. Borel, J.F., Baumann, G., Donatsch, P., Fahr, A., Mueller, E.A., Vigouret, J.M. In vivo pharmacological effects of cyclosporin and some analogues. In: Advances in Pharmacology, Vol. 35. August, J.T., Anders, M.W., Murad, F., Coyle, J.T. (Eds.). Academic Press: New York 1996, 115-246.
8. Walker, R.G., d'Apice, A.J. Azathioprine and steroids. In: Kidney Transplantation, 3rd Edition. Morris, P.J. (Ed.). WB Saunders: Philadelphia 1988, 319-41.
9. Baxter, J.D., Forsham, P.H. Tissue effects of glucocorticoids. Am J Med 1972, 53: 573-89.
10. Suthanthiran, M., Strom, T.B. Renal transplantation. New Engl J Med 1994, 331(6): 365-76.
11. O'Keefe, S.J., Tamura, J., Kincaid, R.L., Tocci, M.J., O'Neill, E.A. FK-506 and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 1992, 357: 692-4.
12. Fruman, D.A., Burakoff, S.J., Bierer, B.E. Immunophilins in protein folding and immunosuppression. FASEB 1994, 8: 391-400.
13. Schreiber, S.L. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991, 251: 283-7.
14. Winkler, M., Brinkmann, C., Jost, U., Oldhafer, K., Ringe, B., Pichlmayr, R. Long-term side effects of cyclosporine-based immunosuppression in patients after liver transplantation. Transplant Proc 1994, 26(5): 2679-82.
15. Thiel, G., Bock, A., Spondlin, M. et al. Long-term benefits and risks of cyclosporine A (Sandimmune) - An analysis at 10 years. Transplant Proc 1994, 26(5): 2493-8.
16. Cho, Y.W., Terasaki, P.I. Long-term survival. In: Clinical Transplants 1988. P.I. Terasaki (Ed.). UCLA Tissue Typing Laboratory: Los Angeles 1988, 277.
17. Thorogood, J., Van-Houwelingen, J.C., Van-Rood, J.J., Zantvoorty, F.A., Schreuder, G.M., Persiin, G.G. Factors contributing to long-term kidney graft survival in Eurotransplant. Transplantation 1992, 54(1): 152-8.
18. Myers, B.D., Newton, L., Oyer, P. The case against the indefinite use of cyclosporine. Transplant Proc 1991, 23(1, Pt 1): 41-2.
19. Kasiske, B.L., Heim-Duthoy, K., Ma, J.Z. Elective cyclosporine withdrawal after renal transplantation. A meta-analysis. JAMA 1993, 269: 395-400.
20. Stiller, C.R., Opelz, G. Should cyclosporine be continued indefinitely? Transplant Proc 1991, 23(1, Pt 1): 36-40.
21. Hricik, D.E., Almawi, W.Y., Strom, T.B. Trends in the use of glucocorticoids in renal transplantation. Transplantation 1994, 57(7): 979-89.
22. Suthanthiran, M. Signaling features of T cells: Implications for the regulation of the anti-allograft response. Kidney Int 1993, 44: S3-11.
23. Bell, P.R.F., Briggs, J.D., Calman, K.C. et al. Reversal of acute clinical and experimental organ rejection using large doses of intravenous prednisolone. Lancet 1971, 1: 876.
24. Schwartz, R., Dameshek, W. The effects of 6-mercaptopurine on homograft reactions. J Clin Invest 1960, 39: 952-8.
25. Shinkai, I., Sigal, N.H. Chemistry and biology of the immunosuppressant (-)-FK-506. J Synth Org Chem 1992, 50(6): 522-34.
26. Thomson, A.W., Carroll, P.B., McCauley, J. et al. FK506: A novel immunosuppressant for treatment of autoimmune disease. Semin Immunopathol 1993, 14: 323-44.
27. Sigal, N.H., Dumont, F.J. Cyclosporine A, FK-506, and rapamycin: Pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 1992, 10: 519-60.
28. Thomson, A.W., Woo, J., Fung, J.J., Starzl, T.E. FK506: Pharmacology and molecular action. In: T-Cell Directed Immunointervention. Bach, J.F. (Ed.). Blackwell Scientific Publications: Oxford 1993, 138-53.
29. Suzuki, N., Sakane, T., Tsunematsu, T. Effects of a novel immunosuppressive agent, FK506, on human B-cell activation. Clin Exp Immunol 1990, 79: 240-5.
30. Morris, R.E., Hoyt, E.G., Murphy, M.P., Shorthouse, R. Immunopharmacology of FK506. Transplant Proc 1989, 21(1): 1042-4.
31. Wallemacq, P.E., Reding, R. FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: Clinical, biomedical, and analytical aspects. Clin Chem 1993, 39(11): 2219-28.
32. Jusko, W.J., Piekoszewski, W., Klintmalm, G.B. et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995, 57(3): 281-90.
33. Focus on tacrolimus. Drugs 1993, 46(4): 746-94.
34. Fagiuoli, S., Gasbarrini, A., Azzarone, A., Francavilla, A., Van Thiel, D.H. FK506: A new immunosuppressive agent for organ transplantation. Pharmacology, mechanism of action and clinical applications. Ital J Gastroenterol 1992, 24: 355-60.
35. Ohara, K., Billington, R., James, R.W., Dean, G.A., Nishiyama, M., Noguchi, H. Toxicologic evaluation of FK 506. Transplant Proc 1990, 22(1, Suppl. 1): 83-6.
36. Nielsen, F.T., Leyssac, P.P., Kemp, E., Starklint, H., Dieperink, H. Nephrotoxicity of FK506: A preliminary study on comparative aspects of FK506 and cyclosporine nephrotoxicity. Transplant Proc 1994, 26(6): 3104-5.
37. Porayko, M.K., Seaberg, E. Primary immunosuppression with FK506 versus cyclosporine A (CyA) in liver transplantation (LTx) recipients: Comparison of complications and survival. Hepatology 1993, 18(4): 57A.
38. Shapiro, R., Jordan, M.L., Scantlebury, V.P. et al. A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 1995, 59(4): 485-90.
39. Shapiro, R., Jordan, M., Scantlebury, V. et al. A prospective, randomized trial of FK-506 in renal transplantation - A comparison between double- and triple-drug therapy. Clin Transplant 1994, 8: 508-15.
40. Yokoyama, I., Uchida, K., Fukao, K. et al. FK 506: Long-term study in kidney transplantation. Japanese FK 506 Study Group. Transplant Proc 1995, 27(1): 818-21.
41. Jordan, M.L., Shapiro, R., Vivas, C.A. et al. FK506 "rescue therapy" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994, 6: 860.
42. Ferraresso, M., Kahan, B.D. Immunopharmacology of rapamycin. J Immunol Immunopharmacol 1993, 12: 252-5.
43. Eugui, E.M., Almquist, S.J., Muller, C.D., Allison, A.C. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991, 33: 175-83.
44. Morris, R.E, Hoyt, E.G., Murphy, M.P., Eugui, E.M., Allison, A.C. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990, 22: 1659-62.
45. Steele, D.M., Hullett, D.A., Bechstein, W.O. et al. Effects of immunosuppressive therapy on the rat aortic allograft model. Transplant Proc 1993, 25: 754-5.
46. Hao, L., Calcinaro, F., Gill, R.G., Eugui, E.M., Allison, A.C., Lafferty, K.J. Facilitation of specific tolerance induction in adult mice by PS-61433. Transplantation 1992, 53: 590-5.
47. Platz, K.P., Sollinger, H.W., Hullett, D.A., Eckhoff, D.E., Eugui, E.M., Allison, A.C. RS-61443: A new, potent Immunosuppressive agent. Transplantation 1991, 51: 27-31.
48. Deierhoi, M.H., Hudson, S.L., Phil, D. et al. Experience with mycophenolate mofetil (RS 61443) in renal transplantation at a single centre. Ann Surg 1993, 217: 476-84.
49. Epinette, W.W., Parker, C.M., Jones, E.L., Griest, M.C. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy and safety. J Am Acad Dermatol 1987, 17: 962-71.
50. Sollinger, H.W. for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995, 60: 225-32.
51. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995, 345: 1321-5.
52. Sehgal, S.N., Molnar-Kimber, K., Ocain, T., Weichman, B.M. Rapamycin: A novel immunosuppressive macrolide. Med Res Rev 1994, 14: 1-22.
53. Wood, M.A., Bierer, B.E. Rapamycin: Biological and therapeutic effects, binding by immunophilins and molecular targets of action. Perspect Drug Discov Des 1994, 2: 163-84.
54. 1 arrest complex FKBP12-rapamycin. Nature 1994, 369: 756-61.
55. Morris, R.E. Rapamycins: Antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 1992, 6: 39-87.
56. 1 of an osteosarcoma cell line. J Biol Chem 1993, 268: 22825-9.
57. 1 phase of the cycle. J Cell Physiol 1993, 154: 7-15.
58. Lai, J.H., Tan, H. CD28 signaling causes a sustained down-regulation of InBα which can be prevented by the immunosuppressant rapamycin. J Biol Chem 1994, 269: 30077-80.
59. Zheng, X.X., Strom, T.B., Steele, A.W. Quantitative comparison of rapamycin and cyclosporine effects on cytokine gene expression studied by reverse transcriptase-competitive polymerase chain reaction. Transplantation 1994, 58: 87-92.
60. Aagaard-Tillery, K.M., Jelinek, D. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell Immunol 1994, 156; 493-507.
61. Kim, H.S., Raskova, J., Degiannis, D., Risk, K.J. Effects of cyclosporine and rapamycin on immunoglobulin production by preactivated human B cells. Clin Exp Immunol 1994, 96: 508-12.
62. Whiting, P.H., Woo, J., Adam, B.J., Hasan, N.U., Davidson, R.J., Thomson, A.W. Toxicity of rapamycin - A comparative and combination study with cyclosporin at immunotherapeutic dosage in the rat. Transplantation 1991, 52: 203-8.
63. Almond, P.S., Moss, A., Nakhleh, R.E. et al. Rapamycin: Immunosuppression, hyporesponsiveness, and side effects in a porcine renal allograft model. Transplantation 1993, 56: 275-81.
64. Whiting, P.H., Adam, B.J., Woo, J., Hasan, N.U., Thomson, A.W. The effect of rapamycin on renal function in the rat. A comparative study with cyclosporine. Toxicol Lett 1991, 58: 169-79.
65. Morris, R.E., Meiser, B.M., Wu, J., Shorthouse, R., Wang, J. Use of rapamycin for the suppression of alloimmune reactions in vivo: Schedule dependence, tolerance induction, synergy with cyclosporine and FK506 and effect on host-versus-graft and graft versus host reactions. Transplant Proc 1991, 23: 521-4.
66. Makowka, L., Cramer, D.V. Brequinarsodium: A new immunosuppressive drug for transplantation. Transplant Sci 1992, 2: 50.
67. Makowka, L., Sher, L.S., Cramer, D.V. The development of brequinar as an immunosuppressive drug for transplantation. Immunol Rev 1993, 136: 51-70.
68. Elion, G.B. Biochemistry and pharmacology of purine analogues. Fed Proc 1967, 26: 898-904.
69. Chen, S.F., Ruber, R., Dexter, D. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2' - fluor - 1,1' - biphenyl - 4 - yl) - 3 - methyl - 4-quinolinecarboxylic acid sodium salt (NSC 368390): Inhibition of de novo pyrimidine nucleotide biosynthesis. Cancer Res 1986, 46: 5014-9.
70. Arteaga, C.L., Brown, T., Kuh, J. et al. Phase I clinical and pharmacokinetic evaluation of brequinar sodium (DUP785; NSC 368390). Cancer Res 1989, 49: 4648-53.
71. Cramer, D.V., Chapman, F.A., Makowka, L. Summation of brequinar sodium symposium. Transplant Proc 1993, 25(Suppl. 2): 83.
72. Chen, S-F., Papp, L.M., Ardecky, R.J. et al. Structure-activity relationship of quinoline carboxylic acids: A new class of inhibitors of dihydroorotate dehydrogenase. Biochem Pharmacol 1990, 40: 709.
73. Cramer, D.V., Chapman, F.A., Jaffee, B.D. et al. The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat. Transplantation 1992, 53: 303.
74. Mizuno, K., Tsujino, M., Takada, M. et al. Studies on bredinin. I. Isolation, characterization and biological properties. J Antibiotics 1973, 27(10): 775-82.
75. Tajima, A., Hata, M., Ohta, N., Ohtawara, Y., Suzuki, K., Aso, Y. Bredinin treatment in clinical kidney allografting. Transplantation 1984, 38(2): 116-8.
76. Kokado, Y., Ishiahi, M., Jiang, H. et al. Low dose cyclosporine, mizoribine, and prednisone in renal transplantation: A new triple drug therapy. Clin Transplant 1990, 4: 191-7.
77. Osakabe, T., Uchida, H., Masaki, Y. et al. Studies on immunosuppression with low-dose cyclosporine combined with mizoribine in experimental and clinical cadaveric renal allotransplantation. Transplant Proc 1989, 21(1): 1598-600.
78. Bartlett, R.R. Immunopharmacological profile of HWA 486, a novel isoxazol derivative - II. In vivo immunomodulating effects differ from those of cyclophosphamide, prednisolone, or cyclosporin A. Int J Immunopharmacol 1986, 8(2): 199-204.
79. Umeda, Y., Moriguchi, M., Kuroda, H. et al. Synthesis and antitumor activity of spergualin analogues. I. Chemical modification of 7-guanidino-3-hydroxyacyl moiety. J Antibiot (Tokyo) 1985, 38: 886-98.
80. Takeuchi, T., Iinuma, H., Kunimoto, S. et al. A new antitumor antibiotic, spergualin: Isolation and antitumor activity. J Antibiot (Tokyo) 1981, 34: 1619-21.
81. Nadler, S.G., Tepper, M.A., Schacter, B., Mazzucco, C.E. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science 1992, 258: 484-6.
82. Lydyard, P.M., Van Eden, W. Heat-shock proteins: Immunity and immunopathology. Immunol Today 1990, 11: 228-9.
83. Hightower, L.E. Heat shock, stress proteins, chaperones, and protcotoxicity. Cell 1991, 66: 191-7.
84. Ellis, R.J. Molecular chaperones. Cell Biol 1990, 1: 1-9.
85. Tufverson, G., Gannedahl, G. Deoxyspergualin -A different and intriguing immunosuppressant. Transplant Proc 1994, 26(5): 3029-39.
86. Takahara, S., Moutabarrik, A., Kokado, Y. et al. Use of 15-deoxyspergualin in treatment of acute rejection in kidney transplant patients. Transplant Proc 1993, 25: 2254.
87. Suzuki, S. Deoxyspergualin: Mode of action and effects on graft rejection. In: Immunosuppressive Drugs: Developments in Anti-rejection Therapy. Thomson, A.W., Starzl, T.E. (Eds.). Little, Brown and Company: Pittsburgh 1994, 14: 187-202.
88. Amemiya, H., Dohi, K., Otsubo, O. et al. Markedly enhanced therapeutic effect of deoxyspergualin on acute rejection when combined with methyprednisolone in kidney recipients. Transplant Proc 1991, 23: 1087-9.
89. Amemiya, H., Suzuki, S., Ota, K. et al. A novel rescue drug, 15-deoxyspergualin. First clinical trials for recurrent graft rejection in renal recipients. Transplantation 1990, 49: 337-43.
90. Bartlett, R.R., Schleyerbach, R. Immunopharmacological profile of a novel isoxazole derivate, HWA 486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol 1985, 7: 7.
91. Bartlett, R.R., Campion, G., Musikic, P., Schleyerbach, R., Zielinski, T., Schorlemmer, H.U. Leflunomide: A novel immunomodulating drug. In: Nonsteroidal Anti-inflammatory Drugs. Mechanisms and Clinical Use. Lewis, A.J., Furst, D.E. (Eds.). Marcel Dekker, Inc.: New York 1994, 349.
92. Bartlett, R.R., Dimitrijevic, M., Mattar, T. et al. Leflunomide (HWA 486), a novel, immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 1993, 32: 10.
93. Schorlemmer, H.U., Seiler, F.R., Bartlett, R.R. Prolongation of allogeneic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxazole derivate. Transplant Proc 1993, 25: 763.
94. Williams, J.W., Xiao, F., Foster, P.F. et al. Immunosuppressive effects of leflunomide in a cardiac allograft model. Transplant Proc 1993, 25: 745.
95. Lang, R., Wagner, H., Heeg, K. Differential effects on the immunosuppressive agents cyclosporine and leflunomide in vivo. Transplantation 1995, 59(3): 382-9.
96. Kupiec-Weglinski, J.W., Schmidbauer, G., Badger, A.M. SK&F 105685: A novel azaspirane with immunosuppressive activities in animal models of autoimmune diseases and organ transplantation. In: Immunosuppressive Drugs: Developments in Anti-rejection Therapy. Thomson, A.W., Starzl, T.E. (Eds.). Little, Brown and Company: Pittsburgh 1994, 16: 213-20.
97. Schmidbauer, G., Hancock, W.W., Badger, A.M., Kupiec-Weglinski, J.W. Induction of non-specific x-irradiation-resistant suppressor cell activity in vivo and prolongation of vascularized allograft survival by SK&F 105685, a novel immunomodulatory azaspirane. Transplantation 1993, 55: 1236-43.
98. Schreier, M.H., Quesniaux, V.F.J., Baumann, G. et al. Molecular basis of immunosuppression. Transplant Sci 1993, 3: 185-9.
99. Lu, C.Y., Sicher, S.C., Vazquez, M.A. Prevention and treatment of renal allograft rejection: New therapeutic approaches and new insights in established therapies. J Am Soc Nephrol 1993, 4: 1239-56.
100. Hidaka, H., Nairn, A.C. (Eds.). Advances in Pharmacology, Vol. 36. Academic Press: New York 1996.
101. Chou, T.C., Stepkowski, S.M., Kahan, B.D. Computerized quantitation of immunosuppressive synergy for clinical protocol design. Transplant Proc 1994, 26(5): 3043-5.
102. Fleiss, J.L. The Design and Analysis of Clinical Experiments. Wiley: New York 1986, 432.
103. Cosimi, A.B. The clinical usefulness of antilymphocyte antibodies. Transplant Proc 1983, 15: 583-7.
104. Raefsky, E.L., Gascon, P., Gratwohl, A., Speck, B., Young, N.S. Biological and immunological characterization of ATG and ALG. Blood 1986, 68: 712-9.
105. Bonnefoy-Berard, N., Vincent, C., Revillard, J.P. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991, 51: 669-73.
106. Kreis, H. Antilymphocyte globulins in kidney transplantation. Kidney Int 1992, 38(Suppl.): S188-92.
107. Kreis, H., Legendre, C., Chatenoud, L. OKT3 in organ transplantation. Transplant Rev 1991, 5: 181.
108. Morel, P., Vincent, C., Cordier, G., Panaye, G., Carosella, E., Revillard, J.P. Anti-CD4 monoclonal antibody administration in renal transplanted patients. Clin Immunol Immunopathol 1990, 56: 311-22.
109. Sablinski, P., Hancock, W.W., Tilney, N.L., Kupiec-Weglinski, J.W. CD4 monoclonal antibodies in organ transplantation - A review of progress. Transplantation 1991, 52: 579-89.
110. Waldmann, T.A., Goldman, C.L. Themultichain interleukin 2 receptor: A target for immunotherapy of patients receiving allografts. Am J Kidney Dis 1989, 14(Suppl. 2): 45-53.
111. Kirkman, R.L., Shapiro, M.E., Carpenter, C.B. et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplant Proc 1991, 23: 1066-7.
112. Cantarovich, D., Le Mauff, B., Hourmant, M. et al. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. Transplantation 1994, 57(2): 198-203.
113. Van Gelder, T., Zietse, R., Mulder, A.H. et al. A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation. Transplantation 1995, 60(3): 248-52.
114. LeMauff, B., Hourmant, M., Rougier, J.P. et al. Effect of anti-LFA1 (CD11a) monoclonal antibodies in acute rejection in human kidney transplantation. Transplantation 1991, 52: 291-6.
115. Maraninchi, D., Mawas, C., Stoppa, A.M. et al. Anti LFA1 monoclonal antibody and bone marrow graft rejection in adults. Lancet 1988, 2(8610): 579-80.
116. Dumont, F.J., Starvch, M.J., Koprak, S.L. et al. Distinct mechanisms of immunosuppression of murine T cell activation by related macrolides FK506 and rapamycin. J Immunol 1990, 144: 251.
117. Tan, P., Anasetti, C., Hansen, J.A. et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993, 177: 165-73.
118. Isobe, M., Yagita, H., Okumura, K., Ihara, A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992, 255: 1125-7.
119. Pearson, T.C., Alexander, D.Z., Winn, K.J., Linsley, P.S., Lowry, R.P., Larsen, C.P. Transplantation tolerance induced by CTLA4-Ig. Transplantation 1994, 57(12): 1701-6.
120. Tykocinski, M.L., Kaplan, D.R. Prospects for anti-rejection therapies based upon CD8-dependent immunoregulation. Kidney Int 1993, 43(39): S120-3.
121. Chester, K.A., Hawkins, R.E. Clinical issues in antibody design. Trends Biotechnol 1995, 13(8): 294-300.
122. Goss, J.A., Nakafusa, Y., Flye, M.W. Intrathymic injection of donor alloantigens induces donor-specific vascularized allograft tolerance without immunosuppression. Ann Surg 1992, 216: 409-16.
123. Buelow, R., Burlingham, W.J., Clayberger, C. Immunomodulation by soluble HLA class I. Transplantation 1995, 59(5): 649-54.
124. Chaudhy, V.K., Queen, C., Junghans, R.P. et al. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 1989, 339: 394-7.
125. Isaacs, J.D., Watts, R.A., Hazleman, B.L. et al. Humanized monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992, 340: 748-52.
126. Mathieson, P.W., Cobbold, S.P., Hale, G. Monoclonal antibody therapy in systemic vasculitis. New Engl J Med 1990, 323: 250-4.
127. Richardson, J.H., Marasco, W.A. Intracellular antibodies: Development and therapeutic potential. Trends Biotechnol 1995, 13: 306-10.
128. Waldmann, T.A. Monoclonal antibodies in diagnosis and therapy. Science 1991, 252: 1657-62.
129. Winter, G., Milstein, C. Man-made antibodies. Nature 1991, 349: 293-9.
130. Duan, L., Zhu, M., Bagasra, O., Pomerantz, R.J. Intracellular immunization against HIV-1 infection of human T lymphocytes: Utility of antirev single-vein variable fragments. Hum Gene Ther 1995, 6(12): 1561-73.